SI1948620T1 - Dihidrogen fosfatna sol antagonista prostaglandin D2 receptorja - Google Patents

Dihidrogen fosfatna sol antagonista prostaglandin D2 receptorja

Info

Publication number
SI1948620T1
SI1948620T1 SI200631572T SI200631572T SI1948620T1 SI 1948620 T1 SI1948620 T1 SI 1948620T1 SI 200631572 T SI200631572 T SI 200631572T SI 200631572 T SI200631572 T SI 200631572T SI 1948620 T1 SI1948620 T1 SI 1948620T1
Authority
SI
Slovenia
Prior art keywords
prostaglandin
receptor antagonist
dihydrogen phosphate
phosphate salt
salt
Prior art date
Application number
SI200631572T
Other languages
English (en)
Inventor
Beverly Langevin
Edward Orton
Daniel Sherer
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of SI1948620T1 publication Critical patent/SI1948620T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/12Ophthalmic agents for cataracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200631572T 2005-10-13 2006-10-12 Dihidrogen fosfatna sol antagonista prostaglandin D2 receptorja SI1948620T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72629005P 2005-10-13 2005-10-13
PCT/US2006/039901 WO2007047378A2 (en) 2005-10-13 2006-10-12 Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
EP06825836A EP1948620B1 (en) 2005-10-13 2006-10-12 Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist

Publications (1)

Publication Number Publication Date
SI1948620T1 true SI1948620T1 (sl) 2013-05-31

Family

ID=37963090

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200631572T SI1948620T1 (sl) 2005-10-13 2006-10-12 Dihidrogen fosfatna sol antagonista prostaglandin D2 receptorja

Country Status (36)

Country Link
US (1) US7642249B2 (sl)
EP (1) EP1948620B1 (sl)
JP (1) JP2009511591A (sl)
KR (1) KR101365480B1 (sl)
CN (1) CN101287714B (sl)
AR (1) AR058085A1 (sl)
AU (1) AU2006304187B2 (sl)
BR (1) BRPI0617311A2 (sl)
CA (1) CA2625563C (sl)
CR (1) CR9870A (sl)
DK (1) DK1948620T3 (sl)
DO (2) DOP2006000220A (sl)
EC (1) ECSP088362A (sl)
ES (1) ES2409833T3 (sl)
GT (1) GT200600457A (sl)
HK (1) HK1125133A1 (sl)
HN (1) HN2008000603A (sl)
HR (1) HRP20130341T1 (sl)
IL (1) IL190673A (sl)
MA (1) MA30005B1 (sl)
MY (1) MY145648A (sl)
NI (1) NI200800116A (sl)
NO (1) NO20082072L (sl)
NZ (1) NZ567433A (sl)
PE (1) PE20070791A1 (sl)
PL (1) PL1948620T3 (sl)
PT (1) PT1948620E (sl)
RS (1) RS52799B (sl)
RU (1) RU2419614C2 (sl)
SI (1) SI1948620T1 (sl)
TN (1) TNSN08131A1 (sl)
TW (1) TW200728288A (sl)
UA (1) UA93062C2 (sl)
UY (1) UY29862A1 (sl)
WO (1) WO2007047378A2 (sl)
ZA (1) ZA200802586B (sl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
DOP2007000068A (es) * 2006-04-12 2007-10-31 Sanofi Aventis Us Llc Compuestos de amino-pirimidina 2,6-sustituidos-4-monosustituidos como antagonistas del receptor de prostaglandina d2
AU2007257841A1 (en) * 2006-06-09 2007-12-21 Icos Corporation Substituted phenyl acetic acids as DP-2 antagonists
ATE531699T1 (de) * 2007-06-29 2011-11-15 Sanofi Sa Verfahren zur herstellung von 2-(3-ä6-ä2-(2,4-
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
WO2010045633A2 (en) * 2008-10-17 2010-04-22 National Jewish Health Measurement and analysis of leukotrienes
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Dp2 길항제 및 이의 용도
WO2012004800A1 (en) 2010-07-08 2012-01-12 Ramot At Tel-Aviv University Ltd. Use of fts and analogs to treat non-autoimmune-allergic and non-allergic inflammatory conditions
EP2621276B1 (en) * 2010-09-30 2017-12-27 Merck Sharp & Dohme Corp. 2-alkoxy pyrimidine pde10 inhibitors
EP3382391A1 (en) 2012-10-24 2018-10-03 NYU Winthrop Hospital Non-invasive biomarker to identify subjects at risk of preterm delivery
WO2016193939A1 (en) 2015-06-04 2016-12-08 Aurigene Discovery Technologies Limited Substituted heterocyclyl derivatives as cdk inhibitors
KR20200109293A (ko) 2017-09-13 2020-09-22 프로제너티, 인크. 자간전증 바이오마커 및 관련된 시스템 및 방법
EP4070113A4 (en) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. ASSESSMENT OF PREECAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR ASSAYS

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60236322D1 (de) * 2001-12-07 2010-06-17 Vertex Pharma Verbindungen auf pyrimidin-basis als gsk-3-hemmer
CA2530538A1 (en) * 2003-07-09 2005-01-20 Keith Roger Bley Thiophenylaminoimidazolines as prostaglandin i2 antagonists
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2

Also Published As

Publication number Publication date
US20080194600A1 (en) 2008-08-14
KR101365480B1 (ko) 2014-02-21
AR058085A1 (es) 2008-01-23
HRP20130341T1 (en) 2013-05-31
WO2007047378A3 (en) 2007-08-02
US7642249B2 (en) 2010-01-05
RU2419614C2 (ru) 2011-05-27
GT200600457A (es) 2007-04-27
PE20070791A1 (es) 2007-08-16
NO20082072L (no) 2008-05-02
NZ567433A (en) 2010-06-25
KR20080057275A (ko) 2008-06-24
UY29862A1 (es) 2007-05-31
AU2006304187B2 (en) 2011-04-28
RS52799B (en) 2013-10-31
RU2008118491A (ru) 2009-11-20
CN101287714A (zh) 2008-10-15
JP2009511591A (ja) 2009-03-19
DOP2006000220A (es) 2007-05-15
WO2007047378A2 (en) 2007-04-26
MY145648A (en) 2012-03-15
EP1948620B1 (en) 2013-03-20
TNSN08131A1 (en) 2009-07-14
PL1948620T3 (pl) 2013-08-30
PT1948620E (pt) 2013-05-06
HK1125133A1 (en) 2009-07-31
CN101287714B (zh) 2011-04-06
ZA200802586B (en) 2009-09-30
MA30005B1 (fr) 2008-12-01
DK1948620T3 (da) 2013-06-24
ES2409833T3 (es) 2013-06-28
TW200728288A (en) 2007-08-01
ES2409833T8 (es) 2013-09-26
AU2006304187A1 (en) 2007-04-26
IL190673A (en) 2011-12-29
EP1948620A2 (en) 2008-07-30
CR9870A (es) 2008-06-18
IL190673A0 (en) 2008-11-03
NI200800116A (es) 2011-12-15
ECSP088362A (es) 2008-05-30
CA2625563A1 (en) 2007-04-26
CA2625563C (en) 2011-04-19
BRPI0617311A2 (pt) 2011-07-19
HN2008000603A (es) 2010-11-03
UA93062C2 (ru) 2011-01-10
DOP2006000223A (es) 2007-05-15

Similar Documents

Publication Publication Date Title
HRP20130341T1 (en) Dihydrogen phosphate salt of a prostaglandin d2 receptor antagonist
IL268462A (en) Dosage form of risedronate
HUS000508I2 (hu) Oszilodrosztát vagy gyógyszerészetileg elfogadható sója, beleértve az oszilodrosztát-dihidrogén-foszfátot
IL184816A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
AP2987A (en) Crystalline form of (R)-3-(-4(2-(2-methyltetrazol-5-YL)pyridin-5-YL)-3-fluorophenyl)-5-hydroxymethyloxazolidin-2-one dihydrogen phosphate
IL213070A (en) A method for determining the efficacy of PD-1 antagonist
TWI365284B (en) Optimization of diffraction order selection for two-dimensional structures
IL189933A0 (en) Rna antagonist compounds for the inhibition of apo-b100 expression
HK1151285A1 (zh) 凝血酶受體拮抗劑的硫酸氫鹽的結晶多晶型物
PT2662380T (pt) Utilização médica de polimorfo a de ibandronato
PT2146944E (pt) Processo para a preparação de folatos marcados com 18f
IL187362A0 (en) Derivatives of a 1-phenyltriazole as antiparasitic agents
IL195903A0 (en) Method of modulating neurite outgrowth by the use of a galanin-3 receptor antagonist
PL380663A1 (pl) Amorficzne postaci rizedronianu monosodowego
HK1126221A1 (en) Process for the preparation of pyrazolylaminoquinazoline derivatives comprising a phosphate group
ZA200806508B (en) Salt of CD80 Antagonist
EP2061492A4 (en) PROCESS FOR AFFECTING PAIN BY MODIFYING NMDA RECEPTORS BY INHIBITION OF SRC
IL186294A0 (en) A process for the preparation of phenyltetrazole compounds
ZA200900208B (en) Xinafoate salt of a substituted 5-oxazol-2-yl-quinoline compound
HK1117141A1 (en) Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form
PL2225187T3 (pl) Otrzymywanie kompozycji opartej na fosforanie potasu
ZA200806494B (en) System for the construction of a semi-prefabricated building
GB0800684D0 (en) Method for determining the status of a body